Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + vincristine + temozolomide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of liposomal irinotecan, vincristine, and temozolomide. Liposomal irinotecan is a formulation of irinotecan encapsulated in liposomes that improves pharmacokinetic profile and potentially reduces toxicity while enhancing efficacy. Vincristine is a vinca alkaloid that acts as a microtubule inhibitor, commonly used in various cancer treatments. Temozolomide is an alkylating agent primarily used for brain tumors, particularly glioblastoma.
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan + vincristine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + vincristine + temozolomide.